Epstein-Barr virus sustains Burkitt's lymphomas and Hodgkin's disease

Trends in Molecular Medicine

Volumn 10, Issue 7, 2004, Pages 331-336

  Hammerschmidt, Wolfgang ^a   Sugden, Bill ^b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR NUCLEAR ANTIGEN 1; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANTIGEN BINDING; APOPTOSIS; B LYMPHOCYTE; BURKITT LYMPHOMA; CELL DEATH; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; LYMPHOMA CELL; MOLECULAR EVOLUTION; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; VIRUS GENE;

APOPTOSIS; BURKITT LYMPHOMA; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; VIRAL MATRIX PROTEINS;

DNA VIRUSES; HUMAN HERPESVIRUS 4;

EID: 3042712903     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2004.05.006     Document Type: Review

References (47)

1. Parkin D.P., et al. The global health burden of infection associated cancers. Cancer Surv. 33:1999;5-33
2. Monto A., Wright T.L. The epidemiology and prevention of hepatocellular carcinoma. Semin. Oncol. 28:2001;441-449
3. Chen H.L., et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. J. Am. Med. Assoc. 276:1996;906-908
4. Tajima K. Malignant lymphomas in Japan: epidemiological analysis of adult T-cell leukemia/lymphoma (ATL). Cancer Metastasis Rev. 7:1988;223-241
5. Hino S., et al. Primary prevention of HTLV-1 in Japan. Leukemia. 11:(Suppl. 3):1997;57-59
6. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer. 2:2002;342-350
7. th edn:1991;386-439 Iowa State University Press
8. Martin G.S. Rous Sarcoma Virus: a function required for the maintenance of the transformed state. Nature. 227:1970;1021-1023
9. Stehelin, et al. Purification of DNA complementary to nucleotide sequences required for neoplastic transformation of fibroblasts by avian sarcoma viruses. J. Mol. Biol. 101:1976;349-365
10. Goodwin E.C., et al. Rapid induction of senescence in human cervical carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 97:2000;10978-10983
11. Jeon S., Lambert P.F. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 92:1995;1654-1658
12. Hsieh J.J., Hayward S.D. Masking of CBF1/RBPJκ transcriptional repression domain by Epstein Barr virus EBNA2. Science. 268:1995;560-563
13. Zimber-Strobl U., Strobl L.J. EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes. Semin. Cancer Biol. 11:2001;423-434
14. Johannsen E., et al. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by Jκ and PU.1. J. Virol. 69:1995;253-292
15. Sjoblom A., et al. PU box-binding transcription factors and a POU domain protein cooperate in the Epstein-Barr virus (EBV) nuclear antigen 2-induced transactivation of the EBV latent membrane protein 1 promoter. J. Gen. Virol. 76:1995;2679-2692
16. Lam N., Sugden B. CD40 and its viral mimic, LMP1: similar means to different ends. Cell. Signal. 15:2002;9-16
17. Mosialos G., et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell. 80:1995;389-399
18. Izumi K.M., Kieff E.D. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB. Proc. Natl. Acad. Sci. U. S. A. 94:1997;12592-12597
19. Kieser A., et al. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J. 16:1997;6478-6485
20. Gires O., et al. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 18:1999;3064-3073
21. Kempkes B., et al. B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J. 14:1995;88-96
22. Kilger E., et al. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 17:1998;1700-1709
23. Rowe M., et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 6:1987;2743-2751
24. Lam K.M., et al. Circulating Epstein-Barr virus-carrying B cells in acute malaria. Lancet. 337:1991;876-878
25. Taub R., et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc. Natl. Acad. Sci. U. S. A. 79:1982;7837-7841
26. Gunven P., et al. Surface immunoglobulins on Burkitt's lymphoma biopsy cells from 91 patients. Int. J. Cancer. 25:1980;711-719
27. Polack A., et al. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc. Natl. Acad. Sci. U. S. A. 93:1996;10411-10416
28. Moss D.J., et al. The immunology of Epstein-Barr virus infection. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:2001;475-488
29. Staege M.S., et al. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells. Proc. Natl. Acad. Sci. U. S. A. 99:2002;4550-4555
30. Leight E.R., Sugden B. EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus. Rev. Med. Virol. 10:2000;83-100
31. Humme S., et al. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc. Natl. Acad. Sci. U. S. A. 100:2003;10989-10994
32. Kirchmaier A.L., Sugden B. Dominant-negative inhibitors of EBNA-1 of Epstein-Barr virus. J. Virol. 71:1997;1766-1775
33. Kennedy G., et al. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc. Natl. Acad. Sci. U. S. A. 100:2003;14269-14274
34. Nanbo A., et al. Epstein-Barr virus RNA confers resistance to interferon-α-induced apoptosis in Burkitt's lymphoma. EMBO J. 21:2002;954-965
35. Crawford D.H. Biology and disease associations of Epstein-Barr virus. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:2001;461-473
36. Küppers R., et al. Biology of Hodgkin's lymphoma. Ann. Oncol. 13:2002;11-18
37. Küppers R., Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu. Rev. Immunol. 16:1998;471-493
38. Lam A., et al. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 90:1997;1073-1083
39. Portis T., Longnecker R. Epstein-Barr virus LMP2A interferes with global transcription factor regulation when expressed during B-lymphocyte development. J. Virol. 77:2003;105-114
40. Portis T., et al. The LMP2A signalosome: a therapeutic target for Epstein-Barr virus latency and associated disease. Front. Biosci. 7:2002;d414-d426
41. Brielmeier M., et al. The latent membrane protein 2 gene of Epstein-Barr virus is important for efficient B cell immortalization. J. Gen. Virol. 77:1996;2807-2818
42. Caldwell R.G., et al. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity. 9:1998;405-411
43. Casola S., et al. B cell receptor signal strength determines B cell fate. Nat. Immunol. 5:2004;317-327
44. Küppers R. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J. Clin. Invest. 111:2003;529-537
45. Portis T., et al. Epstein-Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed/Sternberg cells of Hodgkin lymphoma. Blood. 102:2003;4166-4178
46. Thorley-Lawson D.A. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1:2001;75-82
47. Hochberg D., et al. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc. Natl. Acad. Sci. U. S. A. 101:2004;239-244